Top Page
Abingdon Health PLC
(LSE:ABDX)
Abingdon Health PLC (ABDX) vs. iShares MSCI United Kingdom ETF (EWC)
Abingdon Health PLC Business Overview & Revenue Model
Abingdon Health PLC Financial Statement Overview
| Breakdown | Jun 2025 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.43M | 6.13M | 2.83M | 11.62M | 5.24M |
| Gross Profit | 3.13M | 3.68M | -5.23M | 3.39M | 4.09M |
| EBITDA | -3.12M | -916.00K | -19.98M | -6.07M | -2.84M |
| Net Income | -3.42M | -1.27M | -21.26M | -6.97M | -3.37M |
Balance Sheet | |||||
| Total Assets | 9.31M | 5.09M | 12.77M | 33.23M | 10.97M |
| Cash, Cash Equivalents and Short-Term Investments | 1.92M | 1.44M | 2.40M | 4.98M | 4.39M |
| Total Debt | 1.03M | 1.05M | 1.28M | 1.50M | 4.77M |
| Total Liabilities | 4.01M | 2.84M | 6.34M | 11.90M | 8.22M |
| Stockholders Equity | 5.30M | 2.25M | 6.43M | 21.33M | 2.75M |
Cash Flow | |||||
| Free Cash Flow | -3.43M | -1.70M | -8.49M | -20.13M | 445.00K |
| Operating Cash Flow | -3.10M | -1.66M | -7.74M | -12.88M | 2.10M |
| Investing Cash Flow | -1.43M | -23.00K | -760.00K | -7.28M | -1.94M |
| Financing Cash Flow | 5.08M | -114.00K | 5.92M | 20.74M | 3.37M |
Abingdon Health PLC Technical Analysis
Abingdon Health PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | £264.14M | 11.85 | 6.70% | 3.40% | 17.95% | -54.68% | |
67 Neutral | £112.00M | 15.58 | 8.71% | ― | -1.43% | 28.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.52M | -4.58 | 12.15% | ― | -10.20% | 714.29% | |
47 Neutral | £16.30M | -1.51 | -153.92% | ― | 90.42% | 79.21% | |
45 Neutral | £20.71M | -7.52 | -58.27% | ― | 37.39% | -126.19% | |
40 Underperform | £13.77M | -0.47 | 425.97% | ― | -4.48% | 61.09% |
Abingdon Health PLC Corporate Events
Abingdon Health plc, a U.K.-based med-tech contract service provider, focuses on the development, manufacturing and regulatory support of rapid diagnostic tests, particularly lateral flow and other in vitro diagnostic assays. Serving international customers from facilities in England and the U.S., it offers integrated CDMO, CRO, regulatory and analytical services that take diagnostic products from concept to commercial manufacture across clinical, animal health and environmental markets.
The company has secured a clinical self-test development contract worth about $2.5 million with a U.K. client, covering project management and technical support from feasibility through verification and validation over 18 months. The deal, which will largely contribute revenue in the year to 30 June 2027, reinforces Abingdon Health’s status as a key player in point-of-contact diagnostics and showcases its capability to manage complex, multi-stakeholder international programmes, strengthening its competitive positioning in the global rapid diagnostics sector.
Abingdon will provide end-to-end support via its established lateral flow development, ISO 13485:2016 quality management and regulatory pathway expertise. Management highlighted that this award validates the strategic value of its CDMO and CRO platform to major organisations and underscores its role in advancing global health projects, potentially deepening client relationships and opening further opportunities in the clinical self-test market.
The most recent analyst rating on (GB:ABDX) stock is a Sell with a £7.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health is deepening its US presence by securing quotation for its ordinary shares on the OTCQB Venture Market under the ticker ABDXF, complementing its existing AIM listing in London. The move allows trading in US dollars during US market hours, aiming to broaden the shareholder base among American investors without adding significant reporting costs.
The OTCQB admission follows the second phase of a facility expansion at the company’s Madison, Wisconsin site, which is designed to mirror its UK capabilities and quality systems. By offering customers the choice to have products developed and manufactured in either the US or UK, Abingdon is positioning itself to mitigate tariff and supply-chain risks while targeting increased liquidity and relevance in the world’s largest lateral flow and med-tech market.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health plc, an AIM-quoted international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, focuses on contract development and manufacturing of lateral flow assays and associated regulatory and analytical services for global healthcare and life sciences customers. Founded in 2008 and headquartered in York with facilities in Doncaster and Madison, the group supports clients from concept through to commercial-scale manufacturing and regulatory approval.
The company announced it will release interim results for the six months to 31 December 2025 on 17 March 2026, accompanied by a live online investor presentation that is open to existing and potential shareholders via the Investor Meet Company platform. The planned presentation underlines Abingdon Health’s efforts to maintain active engagement with investors and may provide further clarity on trading performance and strategic progress in its diagnostics and regulatory services businesses.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health reported a 45% rise in first-half FY26 revenues to £4.5m, underpinned by several major commercial contracts and grant-funded development work, while cash more than doubled to £3.6m following an October equity raise of £3.2m to fund its US expansion and support higher-value projects. The board reaffirmed full-year FY26 revenue guidance of £12.6m despite deferring revenue from key customer Find Out From Home into FY27, and said it expects a profitable, cash-generative second half as it scales lateral flow development and manufacturing capacity at its Madison, Wisconsin facility, reinforcing confidence in the company’s growth trajectory and commercial momentum.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health plc, a specialist in rapid diagnostic test development and med-tech regulatory services, has appointed Cavendish Capital Markets Limited as its sole corporate broker and nominated adviser with immediate effect. The move consolidates the company’s advisory and broking relationships under a single City firm, potentially streamlining its access to capital markets and investor engagement as it pursues growth in the international diagnostics and medical device sectors.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health plc, an international developer and manufacturer of rapid lateral flow tests and related regulatory and analytical services, has announced the issuance and admission to trading on AIM of 5,208 new ordinary shares following the exercise of employee share options. The move is a routine capital markets event that increases the company’s total shares in issue to 251,077,850, with no treasury shares held, and provides an updated share capital figure for investors and other stakeholders to use when assessing and disclosing their interests under UK regulatory transparency rules.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health PLC has secured a European patent for its AppDx® lateral flow smartphone reader, which enables the analysis of lateral flow test results via a smartphone’s camera using advanced image processing and deep learning algorithms. This patent further strengthens the company’s intellectual property portfolio and highlights its innovative role in the lateral flow diagnostics industry, supporting its customers with cutting-edge technologies and reinforcing its market positioning.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.